

TIME	NUMBER	TITLE	ROOM
<b>2009-05-10</b>			
<b>SESSION 01: HPV PROPHYLACTIC VACCINES, CLINICAL ASPECTS</b>			<b>SCANIA</b>
13.30-14.05	O-01.00	<b>HPV VACCINATION AND PUBLIC HEALTH: OPPORTUNITY AND CHALLENGE</b> <i>J Paavonen</i>	
14.05-14.18	O-01.01	<b>IMPACT OF HPV VACCINATION DEPENDS ON EFFECTIVE STRATEGY</b> <i>M Lehtinen</i>	
14.18-14.29	O-01.02	<b>IMMUNE RESPONSE AFTER PRIMARY VACCINATION COURSE: A COMPARATIVE TRIAL OF TWO HPV PROPHYLACTIC VACCINES</b> <i>M H Einstein, on behalf of the HPV-010 Study Group</i>	
14.29-14.40	O-01.03	<b>LONG-TERM EFFICACY OF A PROPHYLACTIC HUMAN PAPILLOMAVIRUS TYPE 16 VACCINE</b> <i>A Rowhani - Rahbar, C Mao, FB Alvarez, JT Bryan, SE Hawes, JP Hughes, NS Weiss, LA Koutsky</i>	
14.40-14.51	O-01.04	<b>QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE EFFICACY AGAINST LOW-GRADE GENITAL DISEASE</b> <i>J Dillner, for the GARDASIL phase III investigators</i>	
14.51-15.02	O-01.05	<b>IMPUTED GLOBAL VACCINATION BENEFIT BY KEY RISK PREDICTORS</b> <i>A Rodriguez, Ar Kreimer, S Wacholder, P Gonzalez, M Schiffman, C Porras, D Solomon, R Herrero, A Hildesheim</i>	
15.02-15.13	O-01.06	<b>WHO RECOMMENDATIONS: USE OF HPV VACCINES IN NATIONAL IMMUNIZATION PROGRAMMES</b> <i>KL Irwin, J Hombach, MT Aguado</i>	
15.13-15.24	O-01.07	<b>QUADRIVALENT HPV VACCINE EFFICACY AGAINST MALE GENITAL DISEASE AND INFECTION</b> <i>A Giuliano, J Palefsky</i>	
15.24-15.35	O-01.08	<b>IMPACT OF HPV6/11/16/18 VACCINE ON ABNORMAL PAP TESTS AND PROCEDURES</b> <i>S - O Olsson, J Paavonen</i>	
15.35-15.46	O-01.09	<b>MISCARRIAGE RISK IN TWO RANDOMIZED CONTROLLED TRIALS OF HPV VACCINE</b> <i>S Wacholder, B Chen, A Wilcox, G Macones, P Gonzalez, B Befano, A Hildesheim, A Rodriguez, D Solomon, R Herrero, M Schiffman, for CVT Group</i>	
15.46-15.57	O-01.10	<b>HPV VACCINATION UPTAKE AND REGISTRATION OF HPV VACCINATION IN SWEDEN</b> <i>P Sparén</i>	
<b>SESSION 02: THERAPEUTIC VACCINES AND IMMUNOMODULATION</b>			<b>K1-3</b>
13.30-14.05	O-02.00	<b>THE SPONTANEOUS HPV-SPECIFIC IMMUNE RESPONSE AS A GUIDE FOR IMMUNOTHERAPY</b> <i>S H van der Burg</i>	
14.05-14.16	O-02.01	<b>IMMUNOTHERAPY OF VIN WITH IMIQUIMOD FOLLOWED BY PDT OR VACCINATION</b> <i>P L Stern, S Daayana, E Elkord, U Winters, H Kitchener</i>	
14.16-14.27	O-02.02	<b>POISED HPV16-SPECIFIC T-CELLS IN CERVICAL CARCINOMA AND DRAINING LYMPH NODES</b> <i>P J de Vos van Steenwijk, M Heusinkveld, TH Ramwadhoebe, AM van der Hulst, SJ Piersma, R Goedemans, GG Kenter, SH van der Burg</i>	
14.27-14.38	O-02.03	<b>REGRESSION IS ASSOCIATED WITH CD8 RESPONSES TO HPV 16 E6</b> <i>M Nakagawa, S Gupta, H Coleman, M Sellers, J Banken, W Greenfield</i>	
14.38-14.49	O-02.04	<b>VIRAL VECTOR-BASED PRIME-BOOST IMMUNIZATIONS: A POSSIBLE INVOLVEMENT OF T-CELL COMPETITION</b> <i>T Daemen, A. de Mare, A.J.A. Lambeck, J. Regts, G.M. van Dam, H.W. Nijman, H. Snippe, J Wilschut</i>	
14.49-15.00	O-02.05	<b>IFN-KAPPA IS ABOLISHED BY CERVICAL CANCER-ASSOCIATED HUMAN PAPILLOMAVIRUS TYPE16</b> <i>B Rincon - Orozco, G Halec, F Bosch, F Roesl</i>	

TIME	NUMBER	TITLE	ROOM
15.00-15.11	O-02.06	<b>GENITAL IMMUNIZATION WITH HPV PSEUDOVIRIONS INDUCES GENITAL CD8+ T CELLS</b> <i>N J Cuburu, RC Kines, J Roberts, J Nicewonger, BS Graham, CB Buck, D Lowy, J Schiller</i>	
15.11-15.22	O-02.07	<b>DMXAA ENHANCES THERAPEUTIC HPV VACCINE-INDUCED CTL RESPONSES AND ANTITUMOR EFFECTS</b> <i>S Peng, A Monie, Cf Hung, T.-C. Wu</i>	
15.22-15.33	O-02.08	<b>NOVEL IMMUNOTHERAPY TO INDUCE E7-SPECIFIC CTL IN MURINE GENITAL MUCOSA</b> <i>L Decrausaz, M Duc, Ar Goncalves, M Bobst, N Zosso, D Nardelli - Haefliger</i>	
15.33-15.44	O-02.09	<b>HPV-16 E5 DOWN-REGULATES MHC I AND CONTRIBUTES TO VIRAL IMMUNOEVASION</b> <i>M S Campo, S Man, MS Cortese, K Smith, E Dorman</i>	
15.44-15.55	O-02.10	<b>REGULATION OF LANGERHANS CELL NUMBER ACROSS HPV GENERA</b> <i>M Hibma, C-M Leong, J Doorbar, H-S Yoon</i>	

## 2009-05-11

## SESSION 03: EPIDEMIOLOGY OF HPV-ASSOCIATED DISEASES

SCANIA

08.30-09.05	O-03.01	<b>GLOBAL PERSPECTIVE ON HPV AND HPV-ASSOCIATED DISEASES</b> <i>S Franceschi, G Clifford, J Ferlay, S Vaccarella, HR Shin</i>
09.05-09.16	O-03.02	<b>TIME TRENDS IN THE HPV TYPES DISTRIBUTION IN CERVICAL CANCER</b> <i>L Alemany</i>
09.16-09.27	O-03.03	<b>THE ROLE OF CO-FACTORS IN CERVICAL CANCER IN EPIC COHORT</b> <i>E ROURA, N TRAVIER, C GONZALEZ, F BOSCH, X CASTELLSAGUE</i>
09.27-09.38	O-03.04	<b>IMMUNITY-RELATED CANDIDATE GENES AFFECTING CERVICAL CANCER SUSCEPTIBILITY</b> <i>E Ivansson, J Magnusson, I Gustavsson, L Steiner, P Magnusson, H Erlich, U Gyllensten</i>
09.39-09.49	O-03.05	<b>REDUCED RISK OF CERVICAL AND VULVAR CANCERS ASSOCIATED WITH ALLERGIES</b> <i>L G Johnson, s Schwartz, PL Porter, D Galloway, MM Madeleine</i>
09.49-10.00	O-03.06	<b>GENE POLYMORPHISMS ASSOCIATED WITH CERVICAL CANCER IN SWEDEN</b> <i>F A Castro, K. Haimila, I. Sareneva, M Schmitt, J Bermejo, N. Kunkel, R. Kumar, A. Försti, L Kjellberg, G. Hallmans, M Lehtinen, K. Hemminki, M Pawlita</i>

## SESSION 04: CERVICAL SCREENING &amp; COLPOSCOPY

SCANIA

11.00-11.10	O-04.01	<b>INACCURACY OF COLPOSCOPIC-DIRECTED BIOPSY</b> <i>RG Pretorius</i>
11.10-11.20	O-04.02	<b>NEGATIVE SCREENING NOR COLPOSCOPY PROVIDES ABSOLUTE REASSURANCE AGAINST CERVICAL CANCER</b> <i>P Castle, A Rodriguez, Rd Burk, R Herrero, A Hildesheim, D Solomon, M Sherman, J Jeronimo, M. Alfaro, J. Morales, D. Guillen, M. Hutchinson, S Wacholder, M Schiffman</i>
11.20-11.30	O-04.03	<b>PAP SMEAR COLLECTION POTENTIATES HPV16 INFECTION IN A MACAQUE MODEL</b> <i>D Lowy, J Roberts, Rc Kines, H Katki, C Thompson, Cb Buck, M Bernardo, P Choyke, J Schiller</i>
11.30-11.40	O-04.04	<b>THE ACCURACY OF COLPOSCOPIC BIOPSY: DATA FROM THE GARDASIL TRIALS</b> <i>M Stoler, A Ferenczy, D Ferris, G Perez, E Joura, R Haupt, H Sings, S Lu, P James, M Vichnin</i>
11.40-11.50	O-04.05	<b>CERVIX CANCER SUBSEQUENT TO ALTERNATIVE SCREENING METHODS: PROSPECTIVE RANDOMISED STUDY</b> <i>P Nieminen, A Arun Pokhrel, M Hakama, L Kotaniemi - Talonen, A Anttila</i>
11.50-12.00	O-04.06	<b>RISK OF CERVICAL CANCER AND MANAGEMENT OF ABNORMAL PAP SMEARS</b> <i>L Silfverdal, L Kemetli, B Andrae, P Sparén, W Ryd, J Dillner, B Strander, S Törnberg, S Törnberg, S Törnberg</i>
12.00-12.10	O-04.07	<b>AUDIT OF THE FINNISH SCREENING PROGRAM FOR CERVICAL CANCER</b> <i>S Lönnberg, P Nieminen, A Anttila</i>

TIME	NUMBER	TITLE	ROOM
12.10-12.20	O-04.08	<b>EXTENSION AND PROCESS PERFORMANCE OF EUROPEAN CERVICAL CANCER SCREENING PROGRAMMES</b> <i>G Ronco, M Van Ballegooijen, N Becker, A Chil, F Muriel, P Giubilato, J Kurtinaitis, L Lancucki, E Lyng, A Morais, M O'Reilly, P Sparen, O Suteu, M Rebolj, P Veerus, M Zakelji, A Anttila</i>	
12.20-12.30	O-04.09	<b>NBI COLPOSCOPY IS CRITICAL TO SELECT CIN3 FROM CIN2/3 PATIENTS</b> <i>T Fujii, M Nakamura, T Iwata, A Ohno, H Nishio, M Saito, D Aoki</i>	
<b>SESSION 05: PENILE AND ANAL DISEASES</b>			<b>SCANIA</b>
14.00-15.00	O-05.00	<b>HPV 6/11 DISEASE – EPIDEMIOLOGY, TREATMENT, AND PREVENTION</b> <i>C J N Lacey</i>	
15.00-15.10	O-05.01	<b>ACQUISITION AND CLEARANCE OF ANAL HPV AMONG WOMEN</b> <i>M T Goodman, YB Shvetsov, P Thompson, LR Wilkens, BY Hernandez</i>	
15.10-15.20	O-05.02	<b>ANAL HPV-16 DNA VIRAL LOAD AND NEOPLASIA AMONG MSM</b> <i>C Wang, Q Feng, S Cherm, D Kenney, N Kiviat, Se Hawes</i>	
15.20-15.30	O-05.03	<b>WORLDWIDE HPV CONTRIBUTION AND GENOTYPE DISTRIBUTION IN INVASIVE PENILE CANCER</b> <i>C Miralles, on behalf of the HPV VVAPO study group</i>	
<b>SESSION 06: EPIDEMIOLOGY OF HPV INFECTION</b>			<b>SCANIA</b>
16.00-16.35	O-06.00	<b>ASPECTS OF HPV NATURAL HISTORY THAT INFORM VACCINATION AND SCREENING</b> <i>M Schiffman</i>	
16.35-16.46	O-06.01	<b>RATE OF AND RISKS FOR SECOND INFECTIONS IN YOUNG WOMEN</b> <i>A B Moscicki, Y Ma, S Farhat, S Shiboski</i>	
16.46-16.57	O-06.02	<b>HPV IN OLDER WOMEN IS ASSOCIATED WITH NEW SEXUAL PARTNERS</b> <i>H Trottier, S Ferreira, JCM Prado, JS Sobrinho, MC Costa, LL Villa, E Franco</i>	
16.57-17.08	O-06.03	<b>GENETIC VARIANTS IN HPV-BINDING GENES AND RISK FOR HPV PERSISTENCE</b> <i>A Hildesheim, P Gonzalez, K Yu, C Porras, M Safaeian, A Rodriguez, J Li, M Sherman, C Bratti, M Schiffman, S Wacholder, Rd Burk, S Chanock, R Herrero, S Wang</i>	
17.08-17.19	O-06.04	<b>ONE HPV VIRUS, ONE LESION AS DETERMINED BY LCM/PCR TECHNOLOGY</b> <i>W Quint, A Molijn, B Colau, M van der Sandt, D Jenkins</i>	
17.19-17.30	O-06.05	<b>NATURAL HISTORY OF HPV INFECTIONS AND VULVAR DISEASE DEVELOPMENT</b> <i>E Jaura, R Insinga, H Sings, R Haupt, S Garland</i>	
<b>SESSION 07: EXPERIMENTAL THERAPEUTICS</b>			<b>K1-3</b>
08.30-08.41	O-07.01	<b>IMPACT OF TUMOR-INFILTRATING HPV-SPECIFIC T-REGULATORY CELLS IN CERVICAL CANCER PATIENTS</b> <i>Sj Piersma, Jm van der Hulst, Es Jordanova, Gg Kenter, Sh van der Burg</i>	
08.41-08.53	O-07.02	<b>CLEARANCE OF HPV IN VIN: NORMALIZATION OF IMMUNOCOMPETENT CELL COUNTS</b> <i>L Blok, A Terlou, A Kleinjan, M Van Seters, C Heijmans - Antonissen, I Beckmann, M Van Beurden, T Helmerhorst</i>	
08.53-09.05	O-07.03	<b>IMMUNE THERAPEUTIC STRATEGIES FOR PREINVASIVE HPV DISEASE</b> <i>CL Trimble</i>	
09.05-09.16	O-07.04	<b>HPV PSEUDOVIRIONS AS VEHICLES FOR GENETIC IMMUNIZATION AND GENE THERAPY</b> <i>RC Kines, BS Graham, J Nicewonger, TR Johnson, J Roberts, CB Buck, D Lowy, J Schiller</i>	
09.16-09.27	O-07.05	<b>REQUIREMENTS FOR EFFECTIVE IMMUNOTHERAPY OF CHRONIC VIRAL INFECTION IN SKIN</b> <i>GR Leggatt, J Zhong, S Mattarollo, X Liu, R De Kluver, S Fiorenza, J Zhou, U Hadis, N Warif, A Rahimpour, J Broom, I Frazer</i>	
09.27-09.38	O-07.06	<b>T-CELL IMMUNITY OF THERAPEUTIC VACCINATED PATIENTS CORRELATES WITH CLINICAL RESPONSES</b> <i>MJP Welters, GG Kenter, APG Vloon, MJG Löwik, TMA Berends - van der Meer, F Essahsah, JW Drijfhout, ARPM Valentijn, LM Fathers, J Oostendorp, GJ Fleuren, CJM Melief, SH van der Burg</i>	

TIME	NUMBER	TITLE	ROOM
09.38-09.49	O-07.07	<b>HPV16 IMMUNE ESCAPE IS INDUCED BY THE MINOR CAPSID PROTEIN</b> <i>A. Raff, L. Fahey, D Da Silva, Wm Kast</i>	
09.49-10.00	O-07.08	<b>COMBINED THERAPY WITH AD-LIGHT AND HPV16E6E7-VRP INDUCES SIGNIFICANT TUMOR REGRESSION</b> <i>S Kanodia, D Da Silva, T Karamanukyan, L Bogaert, YX Fu, WM Kast</i>	
<b>SESSION 08: VIRUS LIFE CYCLE</b>			<b>K1-3</b>
11.00-11.11	O-08.01	<b>LOW- AND HIGH-RISK HUMAN PAPILLOMAVIRUS E7 PROTEINS REGULATE P130 DIFFERENTLY</b> <i>A Roman, L Barrow - Laing</i>	
11.11-11.22	O-08.02	<b>HPV E7 INDUCES G2 ARREST FOLLOWING S-PHASE IN DIFFERENTIATED KERATINOCYTES</b> <i>N.S. Banerjee, L.T. Chow, N.J. Genovese, H.K. Wang, T.R. Broker</i>	
11.22-11.33	O-08.03	<b>HPV-31 REQUIRES ATM ACTIVITY FOR REPLICATION IN DIFFERENTIATING CELLS</b> <i>C Moody, L Laimins</i>	
11.33-11.44	O-08.04	<b>GENOMIC INSTABILITY INDUCED BY THE HIGH RISK HUMAN PAPILLOMAVIRUSES</b> <i>M Ustav, T Laos, H Isok - Paas, E Ustav, M Kadaja</i>	
11.44-11.55	O-08.05	<b>ROLE OF L2 CYSTEINES IN INFECTION AND NEUTRALIZATION BY RG-1</b> <i>R Roden, S Jagu, B Karanam, P Day, R Gambhira</i>	
11.55-12.06	O-08.06	<b>HPV16 L2 INTRAMOLECULAR DISULFIDE BOND IS CRITICAL FOR INFECTIVITY</b> <i>M Ozburn, S Campos</i>	
12.06-12.17	O-08.07	<b>TISSUE TROPISM OF CANINE PAPILLOMAVIRUS IS DETERMINED INVIVO AND KERATINOCYTE-INDEPENDENT</b> <i>H Yuan, D Zhou, M Marko, J Wang, R Tucker, X Liu, R Schlegel</i>	
12.17-12.28	O-08.08	<b>TOWARDS AN UNDERSTANDING OF PAPILLOMAVIRUS LATENCY USING THE ROPV MODEL</b> <i>G Maglennon, P McIntosh, J Doorbar</i>	
<b>SESSION 09: VIRAL GENOME REPLICATION AND ANTIVIRALS</b>			<b>K1-3</b>
15.00-15.30	O-09.00	<b>ANALYSIS OF PAPILLOMAVIRUS INITIATION OF DNA REPLICATION</b> <i>A Stenlund, S Schuck</i>	
16.00-16.11	O-09.01	<b>DRUG-LIKE COMPOUNDS THAT INHIBIT HPV-16 E6</b> <i>E Androphy, J Baleja, J Cherry</i>	
16.11-16.22	O-09.02	<b>HPV-11 E1 RELOCALIZES MRE11 AND NBS1 TO REPLICATION CENTERS</b> <i>L.T. Chow, L.L. Dao, J.H. Yu, T.R. Broker</i>	
16.22-16.33	O-09.03	<b>MITOGEN-ACTIVATED PROTEIN KINASES ARE CRUCIAL FOR HPV DNA AMPLIFICATION</b> <i>J.H. Yu, T.R. Broker, B.Y. Lin, H.K. Wang, L.T. Chow</i>	
16.33-16.44	O-09.04	<b>TRANSCRIPTION FACTOR REQUIREMENT FOR E2 MEDIATED PLASMID SEGREGATION</b> <i>T Silla, A Männik, M Ustav</i>	
16.44-16.55	O-09.05	<b>PAK3 INHIBITORS IDENTIFIED BY HIGH-THROUGHPUT-SCREENING AS THERAPEUTICS FOR HPV-ASSOCIATED CANCERS</b> <i>K Hellner, A Baldwin, J Xian, R Stein, M Glicksman, K Munger</i>	
16.55-17.06	O-09.06	<b>RHO KINASE INHIBITION INCREASES KERATINOCYTE PROLIFERATION AND HPV DNA REPLICATION</b> <i>A McBride, S Chapman</i>	
17.06-17.17	O-09.07	<b>DIFFERENTIAL METHYLATION OF HPV16-URR DURING EPITHELIAL DIFFERENTIATION AND NEOPLASTIC TRANSFORMATION</b> <i>S Vinokurova, M Reuschenbach, C Sutter, F Kommos, D Schmidt, M von Knebel Doeberitz</i>	
17.17-17.28	O-09.08	<b>COX-2 AND PGE-2 - TARGETS IN RECURRENT RESPIRATORY PAPILLOMAS</b> <i>B. Steinberg, R. Wu, A. Abramson, M Shikowitz</i>	

2009-05-12

SESSION 10: CELLULAR IMMUNOLOGY (BASIC SCIENCES)

SCANIA

TIME	NUMBER	TITLE	ROOM
08.30-09.00	O-10.00	<b>ADVANCES IN MUCOSAL HPV IMMUNOLOGY</b> <i>M Kast</i>	
09.00-09.10	O-10.01	<b>ERADICATION OF VIN3 LESIONS BY VACCINATION WITH LONG PEPTIDES</b> <i>CJM Melief, MJP Welters, ARPM Valentijn, MJG Lowik, R Offringa, JW Drijfhout, J Oostendorp, GJ Fleuren, SH van der Burg, GG Kenter</i>	
09.10-09.20	O-10.02	<b>HUMAN PAPILLOMAVIRUS TYPE-8 EARLY PROTEINS DEREGULATE IMMUNE HOMEOSTASIS IN SKIN</b> <i>S Smola, T Sperling, GP Marcuzzi, C Wickenhauser, H Pfister, S Majewski</i>	
09.20-09.30	O-10.03	<b>DIRECT LONGITUDINAL COMPARISON OF T-CELL RESPONSES TO PROPHYLACTIC HPV VACCINES.</b> <i>SK Pacher, S Lucke, M Seipel, H Perlitz, T Waterboer, M Pawlita, A Schneider, AM Kaufmann</i>	
09.30-09.40	O-10.04	<b>THE ROLE OF TOLL-LIKE RECEPTORS IN HPV-16 PERSISTENCE</b> <i>Il Daud, ME Scott, Y Ma, S Shiboski, S Farhat, AB Moscicki</i>	
09.40-09.50	O-10.05	<b>TUMOR ASSOCIATED MACROPHAGES REGULATION OF ADAPTATIVE IMMUNITY</b> <i>AP Lepique, A Bolpetti, KR Dagasthanli, IM Cuccovia</i>	
09.50-10.00	O-10.06	<b>EP2R AND EP4R: CANDIDATE RECEPTORS FOR HPV16 ON LANGERHANS CELLS</b> <i>L Fahey, Wm Kast</i>	
<b>SESSION 11: COST-EFFECTIVENESS AND MODELLING OF HPV VACCINATION</b>			<b>SCANIA</b>
11.00-11.35	O-11.00	<b>MODELLING THE EPIDEMIOLOGICAL IMPACT OF HPV VACCINES: THE IMPACT OF ASSUMPTIONS ON RECOMMENDED STRATEGIES</b> <i>G P Garnett, I Baussano</i>	
11.35-11.46	O-11.01	<b>COST-EFFECTIVENESS OF HPV-16/18 VACCINATION IN A COUNTRY WITH EFFECTIVE SCREENING.</b> <i>T Westra, R Rogoza, N Ferko, H Tamming, M Drummond, T Daemen, J Wilschut, M Postma</i>	
11.46-11.57	O-11.02	<b>HPV-16/18 VACCINATION IN SPAIN. HEALTH AND ECONOMIC IMPLICATIONS ON SCREENING.</b> <i>M Diaz, J.J Kim, J Ortendahl, M O'Shea, L Bruni, E Ferrer, F Bosch, S de Sanjose, S.J Goldie</i>	
11.57-12.08	O-11.03	<b>MODELING THE IMPACT OF HPV 16/18 VACCINATION ON PAP TEST ABNORMALITIES IN THE UNITED STATES</b> <i>D Datta, H Weinstock, La Koutsky, K Hsu, Er Unger, J Shlay, P Kermdt, K Ghanem, M Hagensee, H Chesson</i>	
12.08-12.19	O-11.04	<b>VIRAL TRANSMISSIBILITY AND NATURAL IMMUNITY INFERRED FROM HPV TRANSMISSION MODELLING</b> <i>JA Bogaards, M Xiridou, H de Graaf, VM Coupé, CJLM Meijer, J Wallinga, J Berkhof</i>	
12.19-12.30	O-11.05	<b>DYNAMIC MODELING OF HPV VACCINE EFFECTIVENESS: IMPACT OF PARTNERSHIP FORMATION</b> <i>N Van de Velde, M Brisson, MC Boily</i>	
<b>SESSION 12: VIRAL ATTACHMENT AND ENTRY</b>			<b>SCANIA</b>
14.00-14.30	O-12.00	<b>THE COMING OF AGE OF EXPERIMENTAL HPV INFECTIONS</b> <i>M A Ozbun</i>	
14.30-14.40	O-12.01	<b>INITIAL STEPS DURING IN VIVO PAPILLOMAVIRUS INFECTION</b> <i>P Day, K Johnson, Rc Kines, J Roberts, C Thompson, D Lowy, J Schiller</i>	
14.40-14.50	O-12.02	<b>CYCLOPHILIN-B MEDIATES CONFORMATIONAL CHANGES OF HPV16 L2 DURING INFECTIOUS ENTRY</b> <i>M Bienkowska - Haba, H.D. Patel, M. Sapp</i>	
14.50-15.00	O-12.03	<b>CYCLOPHILINS FACILITATE INFECTIOUS ENTRY OF HPV16</b> <i>RM Schowalter, DV Pastrana, DE Anderson, P Day, CB Buck</i>	
15.00-15.10	O-12.04	<b>TEMPOROSTRUCTURAL REARRANGEMENTS OF THE HUMAN PAPILLOMAVIRUS L2 EXTERNAL LOOP</b> <i>M Conway, C Meyers</i>	
15.10-15.20	O-12.05	<b>COMPREHENSIVE CELL BIOLOGICAL ANALYSIS OF HPV-16 ENTRY INTO HOST CELLS</b> <i>M Schelhaas, P Day, J Schiller, A Helenius</i>	

TIME	NUMBER	TITLE	ROOM
15.20-15.30	O-12.06	<b>CLATHRIN- AND CAVEOLIN-INDEPENDENT ENTRY OF HPV16 VIA TEMS</b> <i>C Lambert, G Spoden, K Boller, L Florin</i>	
<b>SESSION 13: HUMORAL IMMUNITY</b>			<b>SCANIA</b>
16.00-16.30	O-13.00	<b>L2 MINOR CAPSID PROTEIN-BIOLOGY AND VACCINES</b> <i>R Roden</i>	
16.30-16.40	O-13.01	<b>SEROLOGIC RESPONSE TO EXPERIMENTAL TRANSMISSION OF MFPV-3 IN FEMALE MACAQUES</b> <i>RD Burk, Z Chen, Y Studentsov, C Wood</i>	
16.40-16.50	O-13.02	<b>MULTIPLEX HUMAN PAPILLOMAVIRUS SEROLOGY BASED ON HEPARIN COATING AND VLPS</b> <i>H Faust, P Knekt, J Dillner</i>	
16.50-17.00	O-13.03	<b>SEROEPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS 11, 16 AND 18 IN MEN</b> <i>B Lu, R Viscidi, Y Wu, E Lazzcano - Ponce, L Villa, D Smith, M Papenfuss, M Abrahamsen, A Giuliano</i>	
17.00-17.10	O-13.04	<b>DETERMINANTS OF SEROCONVERSION AMONG HPV-16/18 DNA POSITIVE YOUNG WOMEN</b> <i>C Porras, C Bennett, M Safaeian, A Hildesheim, A Rodriguez, P Gonzalez, S Wacholder, D Solomon, Lj Van Doorn, C Bougelet, W Quint, R Herrero, M Schiffman, for the CVT Group</i>	
17.10-17.20	O-13.05	<b>HPV SEROLOGY IN WOMEN FOLLOWED-UP FOR 36 MONTHS POST PARTUM</b> <i>S Syrjänen, T Waterboer, M Sarkola, Km Michael, M Rintala, K Syrjänen, S Grenman, M Pawlita</i>	
17.20-17.30	O-13.06	<b>IGA ANTIBODIES AND VIRAL LOAD IN HPV INFECTED WOMEN.</b> <i>A L Combita Rojas, M Molano, P Coursaget, A Touzé, N Muñoz, Df Duarte</i>	
<b>SESSION 14: VIRAL GENE EXPRESSION</b>			<b>K1-3</b>
08.30-09.05	O-14.00	<b>PAPILLOMAVIRUS GENE EXPRESSION: PUZZLES AND CHALLENGES</b> <i>Z-M Zheng</i>	
09.05-09.16	O-14.01	<b>ESTABLISHMENT OF TRANSCRIPTION FROM INCOMING VIRAL GENOME REQUIRES L2 PROTEIN</b> <i>M. Sapp, L. Hilbig, M Bienkowska - Haba</i>	
09.16-09.27	O-14.02	<b>ASF/SF2 AND SRP30C REGULATE HPV-16 EARLY AND LATE MRNA SPLICING</b> <i>M Somberg, X Li, S Schwartz</i>	
09.27-09.38	O-14.03	<b>P300 NOT CBP ENHANCES HPV TRANSCRIPTION BY DISTINCT AP-1 COMPLEXES</b> <i>W-M Wang, A Lee, S-y Wu, C-M Chiang</i>	
09.38-09.49	O-14.04	<b>FUNCTIONAL MAPPING OF THE HUMAN PAPILLOMAVIRUS TYPE 16 E1 CISTRON</b> <i>TH Haugen, MJ LACE, JR Anson, LP Turek</i>	
09.49-10.00	O-14.05	<b>A REPORTER SYSTEM TO STUDY HVP SPLICING</b> <i>J.I Gonzalez - Montoya, M Guido, A Garcia - Carranca</i>	
<b>SESSION 15: CUTANEOUS HPV INFECTIONS AND SKIN CANCER</b>			<b>K1-3</b>
11.00-11.11	O-15.01	<b>PROSPECTIVE STUDY OF HPV SEROPOSITIVITY AND NON-MELANOMA SKIN CANCER</b> <i>K Andersson, Km Michael, T Waterboer, T Luostarinen, R Gislefoss, O Forslund, T Hakulinen, M Pawlita, J Dillner</i>	
11.11-11.22	O-15.02	<b>HPV SEROPREVALENCE IN EPIDERMODYSPLASIA VERRUCIFORMIS PATIENTS, HEALTHY RELATIVES AND CONTROLS</b> <i>Km Michael, T Waterboer, H Pfister, M. Gariglio, S Majewski, M Favre, M Pawlita</i>	
11.22-11.33	O-15.03	<b>INDICATIONS FOR AN ASSOCIATION OF HIGH BETAPV-LOADS WITH SKIN CARCINOGENESIS</b> <i>SJ Weissenborn, R Neale, D Abeni, JN Bouwes Bavinck, MCW Feltkamp, A Green, M De Koning, U Wieland, H Pfister, and EPI-HPV-UV-CA group</i>	
11.33-11.44	O-15.04	<b>CLASSIFICATION OF CUTANEOUS HPV-TYPES WITH RESPECT TO THEIR IMMORTALIZATION CAPACITY</b> <i>RDM Steenbergen, D Claassen - Kramer, CJLM Meijer, L Struijk, PZ van der Meijden, MCW Feltkamp, PJ Snijders</i>	

TIME	NUMBER	TITLE	ROOM
11.44-11.55	O-15.05	<b>HPV20E6 ONCOPROTEIN MODIFIES EPITHELIAL DIFFERENTIATION AND INDUCES LIPID ACCUMULATION</b> <i>E Herráez - Hernández, R Nobre, L Langbein, S Kaden, H-J Gröne, Em de Villiers</i>	
11.55-12.06	O-15.06	<b>MASTOMYS COUCHA: A MODEL FOR PV-INDUCED PATHOGENESIS OF THE SKIN</b> <i>K Schaefer, T Waterboer, M Mueller, J Nafz, I Nindl, F Roesl</i>	
12.06-12.17	O-15.07	<b>IDENTIFICATION OF B-CELL EPITOPES ON VLPS OF CUTANEOUS SPECIES ALPHA-HPVS</b> <i>T Senger, Mr Becker, L Schädlich, T Waterboer, Cb Buck, L Gissmann</i>	
12.17-12.28	O-15.08	<b>MERKEL-CELL-POLYOMAVIRUS IS PREVALENT IN SKIN AND MUCOSA INDEPENDENT OF HPV-STATUS</b> <i>U Wieland, C Mauch, A Kreuter, T Krieg, SJ Weissenborn, H Pfister</i>	
<b>SESSION 16: HPV AMONG THE HIV INFECTED</b>			<b>K1-3</b>
14.00-14.11	O-16.01	<b>SCREEN-AND-TREAT USING HPV TESTING IS HIGHLY EFFECTIVE AMONG HIV-INFECTED WOMEN</b> <i>L Kuhn, L Denny, M DeSousa, T Wright</i>	
14.11-14.22	O-16.02	<b>SAFETY AND IMMUNOGENICITY OF GARDASIL® IN HIV-INFECTED CHILDREN</b> <i>AB Moscicki, A Weinberg, L-Y Song, E Handelsman, J Patterson, A Saah, D Radley, JS Read, C Sattler, M Levin</i>	
14.22-14.33	O-16.03	<b>HLA ASSOCIATIONS WITH HPV/SIL DECREASE WITH IMMUNOSUPPRESSION IN HIV-POSITIVE WOMEN</b> <i>H Strickler, M Martin, X Xue, Rd Burk, A Hildesheim, H Minkoff, L. S Massad, K Anastos, A Kovacs, M Fazzari, G D'Souza, T Harris, M Young, V Bonagura, J Palefsky, M Carrington</i>	
14.33-14.44	O-16.04	<b>HIGH EXPRESSION PROTEINS IN HIV/HPV CO-INFECTED WOMEN</b> <i>A Nicol, G Nuovo, B Grinsztejn, A Pires, S Souza, A Tristão, F Russomano, L Velasque, K C Pessanha, J R Lapa e Silva, C Pirmez</i>	
14.44-14.55	O-16.05	<b>HIV AFFECTS HPV CONCORDANCE AND VIRAL LOAD IN COUPLES</b> <i>Z Z.A Mbulawa, D Coetzee, D Marais, I Gustavsson, M Hoffman, U Gyllensten, Al Williamson</i>	
14.55-15.06	O-16.06	<b>RISK OF HPV-ASSOCIATED CANCERS AMONG PERSONS WITH AIDS</b> <i>A Chaturvedi, Mm Madeleine, R Biggar, E Engels</i>	
15.06-15.17	O-16.07	<b>ARE EXTIRPATIVE PROCEDURES FOR CIN EFFECTIVE IN HIV-POSITIVE WOMEN?</b> <i>Ll Reimers, D Daniel, S Sotardi, L G Chiu, A Van Arsdale, D L Wieland, J M Leider, D J Gerry, D Gupta, G L Goldberg, H Strickler, Mh Einstein</i>	
15.17-15.30	O-29.07	<b>TYPE-SPECIFIC CERVICO-VAGINAL HPV INFECTION INCREASES RISK OF FEMALE HIV ACQUISITION</b> <i>K.K. Smith - McCune, S. Shiboski, Z. M. Chirenje, T. Magure, J. Tuveson, Y. Ma, M. DaCosta, A.-B. Moscicki, J. Palefsky, R. Mutasa, T. Chipato, A. van der Stratén, G.F. Sawaya, ,</i>	
<b>SESSION 17: HPV AND HEAD &amp; NECK CANCERS</b>			<b>K1-3</b>
16.00-16.13	O-17.01	<b>HPV16 E6 INDUCED PTPN13 LOSS ENHANCES ONCOGENE RELATED MAPK SIGNALING</b> <i>J Lee</i>	
16.13-16.24	O-17.02	<b>ORAL HPV PREVALENCE AMONG HEALTHY MEN INTERNATIONALLY</b> <i>AR Kreimer, A Hildesheim, M Abrahamsen, D Smith, LL Villa, E Lazcano, A Giuliano</i>	
16.24-16.35	O-17.03	<b>MESENCHYMAL TRANSFORMATION DURING TUMOR PROGRESSION IN HPV-RELATED OROPHARYNGEAL CANCER</b> <i>EJ Speel, M Stenner, B Yosef, C Huebbers, SF Preuss, HP Dienes, JP Klussmann, M Odenthal</i>	
16.35-16.46	O-17.04	<b>HUMANA PAPILLOMAVIRUS IN TONSILLAR CANCER, AN EPIDEMIC OF VIRAL CARCINOMA</b> <i>T Dalianis, A Näsman, P Attner, L Hammarstedt, J Du, M Eriksson, G Giraud, S Åhrlund - Richter, L Marklund, D Lindquist, M Romanitan, T Ramqvist, J Lindholm, P Sparen, W Ye, H Dahlstrand, E Munck - Wikland</i>	
16.46-16.57	O-17.05	<b>HPV INFECTION IS ABSENT FROM ESOPHAGEAL CANCER IN CHINA</b> <i>W Wei, J Koshiol, W Chen, Ar Kreimer, J Wang, P Gravitt, J Ren, C C Abnet, F Kamangar, M Gillison, M J Roth, P Zhao, Pe Castle, G Wang, P R Taylor, Z Dong, S M Dawsey, Y Qiao</i>	

TIME	NUMBER	TITLE	ROOM
16.57-17.08	O-17.06	<b>ASSOCIATION BETWEEN CHROMOSOME STABILITY, HPV AND PROGNOSIS IN TONSILLAR CARCINOMA</b> <i>JJ Mooren, SMH Claessen, A Haesevoets, Ahn Hopman, Fcs Ramaekers, JP Klussmann, JJ Manni, B Kremer, EJM Speel</i>	
17.08-17.19	O-17.07	<b>ADENOID-CYSTIC CARCINOMAS OF SALIVARY GLANDS ARE ASSOCIATED WITH HIGH-RISK HPV</b> <i>AE Albers, C Chen, M Hummel, E Glastetter, U Keilholz, AM Kaufmann</i>	
17.19-17.30	O-17.08	<b>NATURAL HISTORY OF ORAL AND ANAL HPV INFECTION.</b> <i>G D´ Souza, E Sugar, M Gillison</i>	

**2009-05-13****SESSION 18: TRANSFORMATION AND CARCINOGENESIS****SCANIA**

08.30-09.05	O-18.00	<b>ROLES OF VIRAL AND HOST FACTORS IN CERVICAL CANCER</b> <i>P Lambert</i>
09.05-09.16	O-18.01	<b>MODULATION OF P63 IN CERVICAL CARCINOMA AND REGULATION BY E6</b> <i>F Thierry, Y Ben Khalifa, M M Tan, D S Toh, S Teissier, M Daynac</i>
09.16-09.27	O-18.02	<b>CUTANEOUS HPV38 INDUCES STABILIZATION OF DELTANP73ALPHA BY A NOVEL MECHANISM</b> <i>r accardi</i>
09.27-09.38	O-18.03	<b>ONCOGENE DISRUPTION OF CELL-CELL SENSING UNDERLIES PHENOTYPIC CHANGE DURING NEOPLASIA</b> <i>J Doorbar, Erin Isaacson, Ken Raj, Q Wang, D Jackson</i>
09.38-09.49	O-18.04	<b>INDUCTION OF GENOMIC INSTABILITY BY THE HPV16 E7 ONCOPROTEIN</b> <i>I Hoffmann, R Bahtz, M Arnold, A Krause, O Cizmecioglu, F Settele</i>
09.49-10.00	O-18.05	<b>IDENTIFICATION AND FUNCTIONAL INVESTIGATION OF GENES INVOLVED IN CERVICAL CARCINOGENESIS</b> <i>M Liesenfeld, B. Rudolph, D Steinbach, L Jansen, S. Mosig, H. Funke, I Runnebaum, M Dürst, C Backsch</i>

**SESSION 19: TREATMENT AND POST-TREATMENT FOLLOW-UP****SCANIA**

11.00-11.11	O-19.01	<b>DEVELOPING OPTIMUM FOLLOW-UP STRATEGIES AFTER CIN TREATMENT; A SCORING SYSTEM(FUSS)</b> <i>M Kyrgiou, G Koliopoulos, I Tsoumpou, P Martin - Hirsch, M Arbyn, E Paraskevaidis</i>
11.11-11.22	O-19.02	<b>HC2 AS TEST OF CURE IN STAGE IA CERVICAL CANCER</b> <i>M Sideri, S Costa, S Boveri, C Casadio, M Sandri, N Spolti, G Negri</i>
11.22-11.33	O-19.03	<b>LONG-TERM INCIDENCE/MORTALITY OF CERVICAL OR VAGINAL CANCER AFTER CIN3-TREATMENT</b> <i>B Strander, J Hällgren, P Sparén</i>
11.33-11.44	O-19.04	<b>MORTALITY AFTER TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA</b> <i>I Kalliala, T Dyba, P Nieminen, T Hakulinen, A Anttila</i>
11.44-11.55	O-19.05	<b>POST-TREATMENT HPV TESTING AND LONG-TERM RISK AT RECURRENCE</b> <i>M Kocken, JA Louwers, WA ter Harmsel, J Berkhof, PJ Snijders, RHM Verheijen, T Helmerhorst, CJLM Meijer</i>
11.55-12.06	O-19.06	<b>HPV TESTING IN THE FOLLOW-UP AFTER CONIZATION</b> <i>A Trope, K Sjøborg, A Eskild, T Eriksen, C Jonassen, U Westerhagen, AK Lie</i>
12.06-12.17	O-19.07	<b>HPV TEST OF CURE REMAINS HIGHLY PREDICTIVE AT 5YRS FOLLOW-UP</b> <i>H Kitchener, C Moore, R Hadwin, L Nelson, P Walker, A Sargent, J Wood, GB Anthony, M Cruickshank</i>
12.17-12.28	O-19.08	<b>SURVEILLANCE AFTER TREATMENT FOR CIN: HPV TESTING IS NOT COST-EFFECTIVE</b> <i>J Melnikow, S Kulasingam, M Kuppermann, LJ Helms, C Slee, G Sawaya</i>

**SESSION 20: HPV-BASED SCREENING I****SCANIA**

14.00-14.13	O-20.01	<b>FOLLOW-UP OF THE NTCC RANDOMISED CONTROLLED TRIAL.</b> <i>G Ronco, N Segnan, A Gillio - Tos, R Rizzolo, A Del Mistro, M Zorzi, P Dalla Palma, F Carozzi, C Naldoni, M Confortini, P Pierotti, P Giorgi Rossi, J Cuzick</i>
-------------	---------	--



TIME	NUMBER	TITLE	ROOM
14.13-14.24	O-20.02	<b>DURABLE BENEFITS OF HPV-BASED SCREEN-AND-TREAT TO 36 MONTHS</b> <i>T Wright, L Denny, M DeSousa, L Kuhn</i>	
14.24-14.35	O-20.03	<b>HART: LONG-TERM FOLLOW-UP AMONG WOMEN SCREENED BY CYTOLOGY AND HPV TESTING</b> <i>J Cusick, D Mesher, A Szarewski, L Cadman, H Cubie, G Hulman, H Kitchener, D Luesley, U Menon, G Terry, M Desai, C Gie, L Ho, C Pickles, P Sasieni</i>	
14.35-14.46	O-20.04	<b>COST-EFFECTIVENESS OF HPV DNA SCREENING IN NON-VACCINATED AND VACCINATED WOMEN</b> <i>J Berkhof, VM Coupé, JA Bogaards, Fj van Kemenade, PJ Snijders, CJLM Meijer</i>	
14.46-14.57	O-20.05	<b>COST-EFFECTIVENESS OF VARIOUS CERVICAL SCREENING MODALITIES IN RURAL CHINA</b> <i>K Canfell, JF Shi, Y Ning, JB Lew, R Legood, FH Zhao, YJ Kang, L Ma, L Simonella, M Smith, YZ Zhang, JF Chen, M Clements, G Clifford, S Francheschi, Y Qiao</i>	
14.57-15.08	O-20.06	<b>ADDITION OF HRHPV TESTING TO CONVENTIONAL CYTOLOGICAL SCREENING: VUSA-SCREEN TRIAL</b> <i>D Rijkaart, J Berkhof, PJ Snijders, CJLM Meijer</i>	
15.08-15.19	O-20.07	<b>AGE-SPECIFIC PERFORMANCE OF HPV DNA TEST IN PRIMARY CERVICAL SCREENING</b> <i>A Anttila, M Leinonen, P Nieminen, L Kotaniemi - Talonen, N Malila, J Tarkkanen, P Laurila</i>	
15.19-15.30	O-20.08	<b>HPV TESTING CAN EXTEND SCREENING INTERVALS; EVIDENCE FROM ARTISTIC TRIAL.</b> <i>C Thomson, H Baysson, M Almonte, M Desai, A Sargent, A Turner, A Bailey, J Peto</i>	
<b>SESSION 21: HPV-BASED SCREENING II</b>			<b>SCANIA</b>
15.30-15.40	O-21.01	<b>PREVENTION BY OFFERING HRHPV-TESTING ON SELF-SAMPLED CERVICOVAGINAL SPECIMENS TRIAL (PROTECT)</b> <i>M Gök, DAm Heideman, FJ Van kemenade, L Rozendaal, J Berkhof, PJ Snijders, CJLM Meijer</i>	
15.40-15.50	O-21.02	<b>NATURAL HISTORIES OF HPV DEFINED BY SELF-SAMPLING</b> <i>AB Moscicki, L Widdice, Y Ma, S Farhat, S Miller - Benningfield, J Jonte, J Jay, C Godwin - de Medina, E Hanson, L Clayton, J Simington, S Shiboski</i>	
15.50-16.00	O-21.03	<b>TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS (HPV) STRATIFIED BY ENDOCERVICAL AND VAGINAL SELF-TEST</b> <i>RG Pretorius, Y Qiao, JL Belinson, H Wang, J Smith, J Li, F Taddeo, S Hu, RJ Burchette</i>	
16.00-16.10	O-21.05	<b>TYPING FOR TRIAGING HPV POSITIVE WOMEN AND EXPECTED VACCINATION EFFECT</b> <i>F Carozzi, G Ronco, A Del Mistro, L De Marco, S Girlando, M Zorzi, P Dalla palma, C Naldoni, M Confortini, P Giorgi Rossi, J Cuzick, R Rizzolo, N Segnan, A Gillio - Tos</i>	
16.10-16.20	O-21.06	<b>HPV TESTING AND CYTOLOGY IN PRIMARY SCREENING IN RURAL CHINA</b> <i>FH Zhao</i>	
16.20-16.30	O-21.07	<b>TRIAGE OF ASCUS/LSIL: META-ANALYSIS OF HPV TEST POSITIVITY RATE</b> <i>M Arbyn, P Martin - Hirsch, F Buntinx, E Paraskevaidis</i>	
<b>SESSION 22: ACCEPTABILITY, BEHAVIOURIAL AND PSYCHOLOGICAL ASPECTS OF</b>			<b>K1-3</b>
08.30-08.43	O-22.01	<b>COLPOSCOPY AFTER CERVICAL DYSPLASIA: PSYCHOLOGICAL ASPECTS</b> <i>C Hellsten, K Sjöström, P Lindqvist</i>	
08.43-08.54	O-22.02	<b>U.S. PHYSICIANS' RECOMMENDATIONS ON SCREENING INTERVALS AND HPV DNA TESTING</b> <i>M Saraiya, Z Berkowitz, R Yabroff, V Benard, L Wideroff, S Kobrin</i>	
08.54-09.05	O-22.03	<b>ASCCP GUIDELINE ADHERENCE ON MANAGEMENT OF DISCORDANT AND ASCUS/HPV - RESULTS</b> <i>M Saraiya, Z Berkowitz, V Benard, L Wideroff, S Kobrin</i>	
09.05-09.16	O-22.04	<b>ATTITUDES TO HPV VACCINATION AMONG PARENTS TO CHILDREN 12-15 YEARS</b> <i>P Sparén, C Young, C Lundholm, T Tran, L Arnheim Dahlström</i>	
09.16-09.27	O-22.05	<b>SOCIO-CULTURAL ISSUES FOR INTRODUCTION OF HPV VACCINE IN LOW-RESOURCE SETTINGS</b> <i>DS LaMontagne, A Bingham, JK Drake, L Menezes</i>	

TIME	NUMBER	TITLE	ROOM
09.27-09.38	O-22.06	<b>EARLY UPTAKE OF HPV VACCINATION IN GERMANY</b> <i>SJ Klug, M Claus, A Ahmad, J König, M Blettner</i>	
09.38-09.49	O-22.07	<b>RISK PERCEPTIONS AFTER HPV VACCINATION</b> <i>JA Kahn, SL Rosenthal, C Morrow, M Shew, DI Bernstein, GD Zimet</i>	
09.49-10.00	O-22.08	<b>CHALLENGES OF DELIVERING SCHOOL-BASED HPV VACCINATION IN MANCHESTER, UK</b> <i>L Brabin, S Roberts, R Stretch, D Baxter, G Chambers, H Kitchener, R McCann</i>	
<b>SESSION 23: TRANSFORMATION AND CARCINOGENESIS II</b>			<b>K1-3</b>
11.00-11.13	O-23.01	<b>CELLULAR ZINC HOMEOSTASIS AS A NATURAL ANTI-HPV BARRIER</b> <i>M Lazarczyk, P Cassonnet, C Pons, Y Jacob, M Favre, M Lazarczyk, m Lazarczyk</i>	
11.13-11.24	O-23.02	<b>NFX1-123 INCREASES HTERT POST-TRANSCRIPTIONALLY IN HPV 16E6-KERATINOCYTES</b> <i>R Katzenellenbogen, P Vliet, D Galloway</i>	
11.24-11.35	O-23.03	<b>PI3K SIGNALLING DURING HPV MEDIATED TRANSFORMATION IN VITRO</b> <i>Fe Henken, Pj Snijders, Cjlm Meijer, Rdm Steenbergen</i>	
11.35-11.46	O-23.04	<b>PHOSPHORYLATION OF HSCRIB REGULATES ITS INTERACTION WITH HPV E6 ONCOPROTEINS.</b> <i>K Nagasaka, L Banks</i>	
11.46-11.57	O-23.05	<b>DOWN-MODULATION OF THE P53-NOTCH1 PATHWAY BY HPV-16 E6</b> <i>T Yugawa, M Narisawa - Saito, M Fujita, T Kiyono</i>	
11.57-12.08	O-23.06	<b>IDENTIFICATION OF THE NUCLEAR TRANSPORT SIGNALS OF HPV16 E7 ONCOPROTEIN</b> <i>J Moroiaru, A Knapp, P McManus, K Bockstall, Z Piccioli</i>	
12.08-12.19	O-23.07	<b>CUTANEOUS HPV38E7 INTERACTS WITH HUMAN EEF1A AND MODULATES ITS FUNCTIONS</b> <i>B Sylla, J. Yue, I. Zanella - Cleon, R. Accardi - Gheit, I. Hussain, M. Becchi, E Oswald, A Alonso, M Tommasino</i>	
12.19-12.30	O-23.08	<b>HPV-16 INFECTION ALTERS CELLULAR MICRORNA EXPRESSION IN SCCHN</b> <i>Al Boster, RL Ferris, SA Khan</i>	
<b>SESSION 24: VIRAL PROTEINS: STRUCTURE AND FUNCTION</b>			<b>K1-3</b>
14.00-14.11	O-24.01	<b>HPV18 E2 PROTEIN STABILITY IS CELL-CYCLE DEPENDENT</b> <i>S Bellanger, C L Tan, WL Nei, P He, F Thierry</i>	
14.11-14.22	O-24.02	<b>POST-TRANSLATIONAL MODIFICATION REGULATES HPV16 E1^E4 PROTEIN STRUCTURE AND FUNCTION</b> <i>J Khan, P McIntosh, C Davy, S Hinz, J Doorbar</i>	
14.22-14.33	O-24.03	<b>MODIFICATION OF HPV18 E1^E4 BY PROTEOLYSIS,CDK AND PKA PHOSPHORYLATION.</b> <i>A Pugh, G KNIGHT, I BELL, S ROBERTS</i>	
14.33-14.44	O-24.04	<b>UP-REGULATION OF P18INK4C EXPRESSION BY HPV E6 VIA P53-MIR-34A PATHWAY</b> <i>X Wang, Z-m Zheng</i>	
14.44-14.55	O-24.05	<b>INTERACTION OF THE E8^E2C REPRESSOR-PROTEIN WITH THE CELLULAR CHD6 PROTEIN</b> <i>J Fertey, T Iftner, F Stubenrauch</i>	
14.55-15.06	O-24.06	<b>USE OF A LUCIFERASE FUSION TO STUDY HPV E2 DEGRADATION</b> <i>D Gagnon, S Joubert, H Sénéchal, A Fradet - Turcotte, S Torre, J Archambault</i>	
15.06-15.17	O-24.07	<b>INTERACTION OF BETA PAPILLOMAVIRUS E2 TETHERING PROTEINS WITH MITOTIC CHROMOSOMES</b> <i>A McBride, A Poddar, V Sekhar</i>	
<b>SESSION 25: PROPHYLACTIC VACCINES (BASIC SCIENCES)</b>			<b>K1-3</b>
15.20-15.31	O-25.01	<b>IN VIVO MECHANISMS OF PROTECTION BY VLP AND L2 VACCINATION</b> <i>J Schiller, RC Kines, C Thompson, S Jagu, R Roden, D Lowy, P Day</i>	
15.31-15.42	O-25.02	<b>STRUCTURAL AND IMMUNOLOGIC ANALYSIS OF DIFFERENTLY MODIFIED HPV16 L1 CAPSOMERES</b> <i>L Schädlich, B Gerlach, T Senger, N Mücke, C Klein, I Bravo, M Müller, L Gissmann</i>	

TIME	NUMBER	TITLE	ROOM
15.42-15.53	O-25.03	<b>HPV16 ANTIBODY EPITOPES FROM VACCINE RECIPIENTS AND FOLLOWING NATURAL INFECTIONS</b> <i>GC Wipf, JJ Carter, LA Koutsky, D Galloway</i>	
15.53-16.04	O-25.04	<b>ANTIBODY RESPONSES IN ORAL FLUID AND SERUM FOLLOWING HPV VACCINATION</b> <i>JJ Carter, A Rowhani - Rahbar, Se Hawes, Jp Hughes, La Koutsky, d Galloway</i>	
16.04-16.15	O-25.05	<b>RECOGNITION PATTERN OF NEUTRALIZING AND NON-NEUTRALIZING ANTI-L2 ANTIBODIES</b> <i>M Müller, A Bolchi, M Tommasino, S Ottonello, I Rubio</i>	
16.15-16.26	O-25.06	<b>CHIMERIC L1/L2 VIRUS-LIKE PARTICLES (VLP) AS POTENTIAL BROAD-SPECTRUM HPV VACCINES</b> <i>C Schellenbacher, R Roden, R Kimbauer</i>	

## 2009-05-14

## SESSION 26: MOLECULAR MARKERS &amp; HPV TESTING METHODS

SCANIA

08.30-08.40	O-26.01	<b>DIAGNOSTIC HPV16 RNA PATTERN DISCRIMINATING MILD AND SEVERE CERVICAL LESIONS</b> <i>M Schmitt, V Dalstein, T Waterboer, C Clavel, L Gissmann, M Pawlita</i>
08.40-08.50	O-26.02	<b>CAN IMMUNOHISTOCHEMISTRY FIX THE DIAGNOSTIC INTERPRETIVE PROBLEMS WITH CERVICAL BIOPSIES?</b> <i>M Stoler, K Atkins, M Galgano, W Brix, S Nassau, P Castle</i>
08.50-09.00	O-26.03	<b>E6/E7 MRNA AND DNA TESTS FOR DETECTION OF <math>\geq</math>CIN II</b> <i>S Ratnam, F Coultee, D Fontaine, J Bentley, N Escott, P Ghatage, G Holloway, E Bartellas, N Kum, C Giede, V Gadag, A Lear</i>
09.00-09.10	O-26.04	<b>COMPARISON OF MEASURES OF VIRAL PERSISTENCE TO PREDICT SUBSEQUENT DISEASE</b> <i>J Gage, M Schiffman, D Solomon, P Castle</i>
09.10-09.20	O-26.05	<b>ABSOLUTE RISK OF SUBSEQUENT CIN3+ ACCORDING TO DIFFERENT HPV TYPES</b> <i>S Kjær, C Munk, K Frederiksen, J Junge, T Iftner</i>
09.20-09.30	O-26.06	<b>AMPLICOR HPV DETECTION IN THE ASCUS-LSIL TRIAGE STUDY</b> <i>N Wentzensen, P Gravitt, D Solomon, C Wheeler, PE Castle</i>
09.30-09.40	O-26.07	<b>EVALUATION OF ABBOTT HIGH RISK HPV DNA ASSAY IN PRIMARY HPV-SCREENING</b> <i>B Hammas, J Dillner, C Wahlström</i>
09.40-09.50	O-26.08	<b>P16INK4A IN CERVICAL CYTOLOGY AND HISTOLOGY: SYSTEMATIC REVIEW AND META-ANALYSIS</b> <i>I Tsoumpou, M Arbyn, M Kyrgiou, N Wentzensen, G Koliopoulos, P Martin - Hirsch, V Malamou - Mitsi, E Paraskevaidis</i>
09.50-10.00	O-26.09	<b>DIGENE HPV GENOTYPING LQ-TEST: HIGH-THROUGHPUT GENOTYPING USING XMAP TECHNOLOGY</b> <i>D Geraets, DAM Heideman, M de Koning, PJ Snijders, DCJG van Alewijk, CJLM Meijer, Lj van Doorn, W Quint</i>

## SESSION 27: HPV INFECTION IN MALES

SCANIA

11.00-11.11	O-27.01	<b>QUADRIVALENT HPV VACCINE EFFICACY IN MEN HAVING SEX WITH MEN</b> <i>J Palefsky, A Giuliano</i>
11.11-11.22	O-27.02	<b>CORRELATES OF PERSISTENT INCIDENT GENITAL HPV INFECTION IN YOUNG MEN</b> <i>Y Arima, J Partridge, R Winer, S-K Lee, Q Feng, Jp Hughes, M Stern, S O'Reilly, La Koutsky</i>
11.22-11.33	O-27.03	<b>HPV IN DANISH MEN. ASSOCIATION WITH CIRCUMCISION-STATUS AND GENITAL WARTS</b> <i>S Kjær, C Munk, B Nøhr, A Nielsen, K Liaw, T Iftner</i>
11.33-11.44	O-27.04	<b>PROBABILITY OF HPV TRANSMISSION AMONG NEWLY-FORMED COUPLES</b> <i>A Burchell, J Hanley, P Tellier, F Coutlée, E Franco</i>
11.44-11.55	O-27.05	<b>CONDOM USE IS ASSOCIATED WITH LOWER HPV PREVALENCE IN MEN</b> <i>CM Nielson, RB Harris, A Nyitray, EF Dunne, KM Stone, A Giuliano</i>

TIME	NUMBER	TITLE	ROOM
11.55-12.06	O-27.06	<b>INTERNATIONAL HPV INCIDENCE AMONG MEN AGES 18-70 YEARS</b> <i>A Giuliano, JH Lee, WJ FULP, LL Villa, E Lazcano, M Papenfuss, D Smith, M Abrahamsen</i>	
12.06-12.17	O-27.07	<b>CONDOMS PREVENT INCIDENT ANAL HUMAN PAPILLOMAVIRUS INFECTION IN MEN</b> <i>P Chin - Hong, E Vittinghoff, D Benet, S Buchbinder, M Da Costa, T Darragh, F Judson, B Koblin, K Mayer, J Palefsky</i>	
12.17-12.28	O-27.08	<b>HIGH ANAL HPV PREVALENCE IN MULTINATIONAL SAMPLES: THE HIM STUDY</b> <i>A Nyitray, D Smith, L Villa, E Lazcano - Ponce, M Abrahamsen, A Giuliano</i>	
<b>SESSION 28: BEST POSTER LECTURES</b>			<b>SCANIA</b>
13.30-13.40	O-28.01	<b>BEST POSTER AWARDS</b>	
13.40-13.50	O-28.02	<b>BEST POSTER AWARD LECTURE NUMBER 1</b> <i>to be announced</i>	
13.50-14.00	O-28.03	<b>BEST POSTER AWARD LECTURE NUMBER 2</b> <i>to be announced</i>	
<b>SESSION 29: LATE BREAKER ABSTRACTS</b>			<b>SCANIA</b>
14.00-14.10	O-29.01	<b>CROSS-PROTECTIVE EFFICACY OF CERVARIX™ AGAINST ONCOGENIC HPV TYPES BEYOND HPV-16/18.</b> <i>R Skinner, D Apter, SN Chow, C Wheeler, G Dubin, for the HPV PATRICIA Study Group</i>	
14.10-14.20	O-29.02	<b>RAPID DECLINE IN WARTS AFTER NATIONAL QUADRIVALENT HPV VACCINE PROGRAM</b> <i>C Fairley, J Hocking, M Chen, B Donovan, C Bradshaw</i>	
14.20-14.30	O-29.03	<b>DEFICIENCY IN THE FANCOMNI ANEMIA PATHWAY SENSITIZES MICE TO HPV-ASSOCIATED HEAD AND NECK CANCER</b> <i>J W Park, K Strati, P Lambert</i>	
14.30-14.40	O-29.04	<b>ARE 2 DOSES OF HPV VACCINE ADEQUATE IN GIRLS ?</b> <i>S Dobson, M Dawar, D Scheifele, T Kollmann, S McNeil, S Halperin, J Langley, M Dionne, M-E Picard, C Sauvageau, M Krajden, F Marra, D Miller, D Money, M Naus, G Ogilvie, J Singer, J Bettinger, E Young</i>	
14.40-14.50	O-29.05	<b>CERVICAL CANCER AMONG IMMIGRANTS IN SWEDEN, FROM 1968 THROUGH 2004</b> <i>F Azerkan, K Zendejdel, P Tillgren, E Faxelid, P Sparén</i>	
14.50-15.00	O-29.06	<b>FINAL PHASE III EFFICACY ANALYSIS OF CERVARIX™ IN YOUNG WOMEN</b> <i>J Paavonen, P Naud, J Salmerón, C Wheeler, S-N Chow, D Apter, H Kitchener, X Castellsague, J Teixeira, SR Skinner, J Hedrick, U Jaisamram, G Limson, SM Garland, A Szarewski, B Romanowski, F Aoki, T Schwarz, WAJ Poppe, X Bosch, D Jenkins, K Hardt, T</i>	
<b>SESSION 30: GLOBAL HPV EPIDEMIOLOGY</b>			<b>K1-3</b>
08.30-08.41	O-30.01	<b>COMPARISON OF SERA AND DRIED BLOOD SPOTS FOR HPV SEROEPIDEMIOLOGY</b> <i>T Waterboer, B Dondog, KM Michael, A Michel, M Schmitt, S Franceschi, G Clifford, M Pawlita</i>	
08.41-08.52	O-30.02	<b>CUMULATIVE 2-YEAR HR-HPV PERSISTENCE AND ACQUISITION IN PERI-URBAN INDIAN WOMEN</b> <i>P Gravitt, H Vedantham, P Paul, B Kalpana, D Vidyadhari, P Sowjanya, G Ramakrishna, K Vijayaraghavan, K Shah</i>	
08.52-09.03	O-30.03	<b>SEROPREVALENCE OF HPV 6, 11, 16, 18 IN UNITED STATES</b> <i>Le Markowitz, M Sternberg, EF Dunne, Er Unger</i>	
09.03-09.14	O-30.04	<b>AGE-SPECIFIC PREVALENCE OF PRECANCEROUS LESIONS OF THE CERVIX: GLOBAL REVIEW</b> <i>J Ting, DT Kruzikas, J Smith</i>	
09.14-09.25	O-30.05	<b>WORLDWIDE HPV TYPE-SPECIFIC PREVALENCE IN CYTOLOGICALLY NORMAL WOMEN (1995-2008)</b> <i>L Bruni, E Ferrer, M Diaz, KS Louie, G Albero, J Muñoz, X Castellsagué, F Bosch, S de Sanjosé</i>	
09.25-09.36	O-30.06	<b>HPV 16 AND 18 NEUTRALIZING ANTIBODY IN PRENATAL WOMEN</b> <i>M Krajden, K Karunakaran, S So, J Palefsky, R Sharma, A Yu, R Chow, S Dobson, G Ogilvie, M Petric</i>	

TIME	NUMBER	TITLE	ROOM
09.36-09.47	O-30.07	<b>HIGH-RISK HPV PERSISTENCE IN DANISH WOMEN FROM THE GENERAL POPULATION</b> <i>A Nielsen, S Kjær, C Munk, M Osler, T Iftner</i>	
09.47-09.58	O-30.08	<b>POPULATION-BASED SEROPREVALENCE OF HUMAN PAPILLOMAVIRUS IN CHINESE WOMEN</b> <i>J Ji, H Wang, W Chen, s Hu, M Esser, C. Velicher, JL Belinson, Rg Pretorius, J Smith, Y Qiao</i>	
<b>SESSION 31: HPV TESTING II</b>			<b>K1-3</b>
11.00-11.10	O-31.01	<b>THE WHO HPV LABNET INTERNATIONAL PROFICIENCY STUDY OF HPV DNA TYPING METHODS</b> <i>C Eklund, T Zhou, J Dillner, and the WHO HPV Laboratory Network</i>	
11.10-11.20	O-31.02	<b>NATIONAL QUALITY ASSURANCE PROGRAM FOR HPV-TESTING AND TYPING IN ITALY</b> <i>F Carozzi, G Venturini, L Ciccocioppo, A Del Mistro, A Gillio - Tos, S Girlando, L De Marco, H Frayle, P Giorgi Rossi, G Ronco, M Confortini, C Tufi, C Sani, HPV QA Working Group</i>	
11.20-11.30	O-31.03	<b>TRANSCRIPTOME PROFILING OF CERVICAL SWABS FROM PERSISTENTLY HPV16 INFECTED WOMEN</b> <i>A Manawapat, S Krüger Kjær, B Schopp, R Russ, A-M Florea, C Munk, T Iftner, F Stubenrauch</i>	
11.30-11.40	O-31.04	<b>KALLICREIN-7 AND SUPEROXIDE DISMUTASE-2 AS PROGRESSION MARKERS OF CERVICAL DISEASE</b> <i>L Termini, PC Maciag, FA Soares, S Nonogaki, VAF Alves, A Longatto - Filho, LL Villa</i>	
11.40-11.50	O-31.05	<b>TRIAGE OF ASC-US AND LSIL CYTOLOGY CASES BY P16 IMMUNOCYTOCHEMISTRY</b> <i>C BERGERON, D KARIN, K PETRA, T MARCUS, R RUDIGER</i>	
11.50-12.00	O-31.06	<b>THE USE OF AN RNA-BASED HPV-TEST IN HPV TRIAGING</b> <i>SW Sørbye, S Fismen, T Gutteberg, ES Mortensen</i>	
12.00-12.10	O-31.07	<b>RESULTS OF THE FRENCH APTIMA HPV SCREENING EVALUATION (FASE STUDY)</b> <i>J Monsonego, P Halfon, L Zerat, M Ricart, F Ruiz, k Syrjänen</i>	
12.10-12.20	O-31.08	<b>A NOVEL BROAD-SPECTRUM PCR-LUMINEX ASSAY FOR IDENTIFICATION OF WART HPV</b> <i>M de Koning, J ter Schegget, M Kamp, B Kleter, Mcw Feltkamp, J Eekhof, JN Bouwes Bavinck, K Purdie, C Harwood, W Quint</i>	
12.20-12.30	O-31.09	<b>HPV MRNA AND P16INK4A AS TRIAGE MARKERS IN CERVICAL CYTOLOGY</b> <i>M Reuschenbach, A Clad, C von Knebel Doeberitz, J Rahmsdorf, R Grote, L Wu, N Wentzensen, M von Knebel Doeberitz</i>	
<b>SESSION 32: TAXONOMY AND HPV DATABASES</b>			<b>K1-3</b>
13.30-13.43	O-32.01	<b>PAPILLOMAVIRUS TAXONOMY: REPORT OF THE ICTV STUDY GROUP.</b> <i>H.U. Bernard, Rd Burk, Em de Villiers, M. van Ranst, H. zur Hausen</i>	
13.43-13.54	O-32.02	<b>PAPILLOMAVIRUS EPISTEME (PAVE): A COMPREHENSIVE PAPILLOMAVIRIDAE DATABASE AND ANALYSIS RESOURCE</b> <i>Y. Huyen, Y. Mohamoud, V. Gopalan, S. Bandaru, J. Nozzi, J. Barnett, A McBride</i>	
13.54-14.05	O-32.03	<b>CHARACTERIZATIONS OF NINE MACACA FASCICULARIS PAPILLOMAVIRUS (MFPV) COMPLETE GENOMES</b> <i>K van Doorslaer, Z Chen, C Wood, Rd Burk</i>	
14.05-14.16	O-32.04	<b>MODELING CARCINOGENIC HPV GENITAL INFECTIONS AND DISEASE WITH RHPV1</b> <i>M Ozbun, J. Maestas, A. Maldonado, N. Patterson, M. Kivitz, N. Joste, P. Marx, V. Traina - Dorge</i>	
14.16-14.27	O-32.05	<b>NOVEL HPV SEQUENCES IN CERVICAL CARCINOMA CONTAINING SINGLE HPV GENOTYPES</b> <i>W Quint, D Geraets, N Guimerà, N Guimerà, M de Koning, LJ van Doorn, S de Sanjosé, F Bosch</i>	
14.27-14.38	O-32.06	<b>ALPHA AND BETA PAPILLOMAVIRUSES DIFFER IN SYNONYMOUS CODON USAGE</b> <i>N Cladel, A Bertotto, N Christensen,</i>	

# PROGRAMME

THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,  
SWEDEN

Oral presentations

Page 14

TIME	NUMBER	TITLE	ROOM
14.38-14.49	O-32.07	<b>EVOLUTION OF PRIMATE ALPHA PAPILLOMAVIRUSES</b> <i>Z Chen, K van Doorslaer, R DeSalle, C Wood, Rd Burk</i>	
14.49-15.00	O-32.08	<b>TOWARDS A TIME SCALE FOR THE EVOLUTION OF PAPILLOMAVIRUSES</b> <i>I Bravo, A Stamatakis, O Bininda - Emonds, M Göker, I Nindl, M Gottschling</i>	